SCHEMBL3317068

SCHEMBL3317068

CCOC(=O)N(C1CCCCC1)C1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
ALDH1A1 P00352 5/20 0.43
TSHR P16473 4/20 0.42
ADH1C P00326 1/20 0.42
ADH1A P07327 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
POLB P06746 1/20 0.42
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
THRB P10828 1/20 0.41
ATM Q13315 1/20 0.41
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
GAA P10253 1/20 0.39
S1PR3 Q99500 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13462953 0.85 ALDH1A1 (0.50) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2
M-Xylene SCHEMBL8433561 0.84 KMT2A (0.46) KMT2AMEN1ALDH1A1TSHRPOLB
Resorcinol SCHEMBL11664139 0.84 KMT2A (0.49) KMT2AMEN1ALDH1A1TSHRPOLB
SCHEMBL10993193 0.84 ALDH1A1 (0.38) KMT2AMEN1ALDH1A1TSHRADH1C
SCHEMBL10912846 0.84 ALDH1A1 (0.48) ALDH1A1L3MBTL1ATMKDM4E
SCHEMBL9357964 0.82 TSHR (0.49) KMT2AMEN1ALDH1A1TSHRADH1C
SCHEMBL14920073 0.82 ALDH1A1 (0.42) KMT2AMEN1ALDH1A1TSHRADH1C
SCHEMBL10388017 0.81 KMT2A (0.37) KMT2AMEN1ALDH1A1TSHRADH1C
SCHEMBL1837926 0.81 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2
SCHEMBL10988348 0.81 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1TSHRADH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0228272-A2 Preparation of urethane substituted diacetylene monomers and polymers GTE LABORATORIES INCORPORATED (US) 1987-07-08 EP claimed
EP-4728003-A1 HUMIDITY CURABLE TWO-COMPONENT SYSTEM COMPRISING ACCELERATOR Zephyros Inc. (US) 2026-04-22 EP disclosed
WO-2024256486-A1 HUMIDITY CURABLE TWO-COMPONENT SYSTEM COMPRISING ACCELERATOR ZEPHYROS, INC. (US) 2024-12-19 WO disclosed
US-20240059891-A1 Composition Comprising Silyl-Modified Prepolymer and Highly Structured Carbon Black ZEPHYROS, INC. 2024-02-22 US disclosed
EP-4259709-A1 COMPOSITION COMPRISING SILYL-MODIFIED PREPOLYMER AND HIGHLY STRUCTURED CARBON BLACK Zephyros Inc. (US) 2023-10-18 EP disclosed
US-11518904-B2 Curable coating compositions SWIMC LLC (US) 2022-12-06 US disclosed
WO-2022122782-A1 COMPOSITION COMPRISING SILYL-MODIFIED PREPOLYMER AND HIGHLY STRUCTURED CARBON BLACK ZEPHYROS, INC. (US) 2022-06-16 WO disclosed
EP-2756353-B1 PATTERN-FORMING METHOD, ELECTRON BEAM-SENSITIVE OR EXTREME ULTRAVIOLET RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, MANUFACTURING METHOD OF ELECTRONIC DEVICE USING THEM AND ELECTRONIC DEVICE FUJIFILM CORP (JP) 2019-05-01 EP disclosed
US-9199934-B2 Alpha-hydroxyketones BASF SE (DE) 2015-12-01 US disclosed
EP-2129659-B1 ALPHA-HYDROXYKETONES BASF SE (DE) 2013-05-29 EP disclosed
US-20100104979-A1 ALPHA-HYDROXYKETONES IGM GROUP B.V. (NL) 2010-04-29 US disclosed
EP-0228272-A2 Preparation of urethane substituted diacetylene monomers and polymers GTE LABORATORIES INCORPORATED (US) 1987-07-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100104979-A1 ALPHA-HYDROXYKETONES C9, C1R, CBR3 KMT2A 2928/4885MEN1 2626/4885ALDH1A1 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.